Related Experiment Videos
[New developments in therapy of deep mycoses].
1Teikyo University Institute of Medical Mycology, 359 Otsuka, Hachioji, Tokyo, 192-0395 Japan.
Nihon Ishinkin Gakkai Zasshi = Japanese Journal of Medical Mycology
|November 7, 2000
Summary
The rising incidence of invasive fungal infections, often resistant to current treatments, necessitates novel antifungal therapies. This review highlights emerging drugs like lipid formulations of amphotericin B, second-generation azoles, and lipopeptides.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Context:
- Increasing incidence of deep mycoses and opportunistic fungal infections over the past two decades.
- Emergence of drug-resistant fungal pathogens, including fluconazole-resistant Candida albicans.
- Challenges in treating invasive fungal infections due to pathogen resistance to existing antifungal drugs.
Purpose:
- To review current approaches in antifungal chemotherapy.
- To focus on the clinical development of new antifungal agents.
- To discuss novel antifungal drugs with potential advantages or complementary roles.
Summary:
- Discusses the rising threat of invasive fungal infections caused by various Candida spp., aspergilli, Cryptococcus neoformans, zygomycetes, and emerging pathogens.
- Highlights the challenge of antifungal drug resistance, complicating clinical treatment outcomes.
- Reviews the clinical development of new antifungal agents, specifically lipid formulations of amphotericin B, second-generation azoles, and antifungal lipopeptides.
Impact:
- Addresses the urgent need for new antifungal agents to combat resistant fungal infections.
- Provides insights into promising new antifungal drug classes for clinical application.
- Aims to improve treatment strategies for difficult-to-treat invasive mycoses.